医药行业：从摩根大通医疗健康大会看生物创新药管线，关注ADC、双特异性抗体、细胞与基因治疗

研报虎2025-02-11

2025年第四十三届摩根大通医疗健康年会（JPM大会）盛大召开。国内百济神州、恒瑞医药、信达生物、康方生物等约30家企业参会，分享了多个重磅品种最新成果，中国创新药成为世界舞台上闪耀的新星。我们从本次会议的热点一窥行业创新升级的重点方向，关注抗体偶联药物（Antibody-Drug Conjugate，ADC）、双特异性抗体、细胞与基因治疗等生物创新药领域的最新进展。一、ADC快速发展，第三代技术...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2510827757?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-02-11 13:59","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2510827757","market":"sh","top_or_hot":-1,"title":"医药行业：从摩根大通医疗健康大会看生物创新药管线，关注ADC、双特异性抗体、细胞与基因治疗","media":"研报虎","content":"<div>\n<p>2025年第四十三届摩根大通医疗健康年会（JPM大会）盛大召开。国内百济神州、恒瑞医药、信达生物、康方生物等约30家企业参会，分享了多个重磅品种最新成果，中国创新药成为世界舞台上闪耀的新星。我们从本次会议的热点一窥行业创新升级的重点方向，关注抗体偶联药物（Antibody-Drug Conjugate，ADC）、双特异性抗体、细胞与基因治疗等生物创新药领域的最新进展。一、ADC快速发展，第三代技术...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211140710abca815b&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>医药行业：从摩根大通医疗健康大会看生物创新药管线，关注ADC、双特异性抗体、细胞与基因治疗</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n医药行业：从摩根大通医疗健康大会看生物创新药管线，关注ADC、双特异性抗体、细胞与基因治疗\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-02-11 13:59 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211140710abca815b&s=b><strong>研报虎</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>2025年第四十三届摩根大通医疗健康年会（JPM大会）盛大召开。国内百济神州、恒瑞医药、信达生物、康方生物等约30家企业参会，分享了多个重磅品种最新成果，中国创新药成为世界舞台上闪耀的新星。我们从本次会议的热点一窥行业创新升级的重点方向，关注抗体偶联药物（Antibody-Drug Conjugate，ADC）、双特异性抗体、细胞与基因治疗等生物创新药领域的最新进展。一、ADC快速发展，第三代技术...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211140710abca815b&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688799","symbol_name":"华纳药厂","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211140710abca815b&s=b","article_id":"2510827757","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211140710abca815b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2510827757","pubTimestamp":1739253565,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"2025年第四十三届摩根大通医疗健康年会盛大召开。我们从本次会议的热点一窥行业创新升级的重点方向，关注抗体偶联药物、双特异性抗体、细胞与基因治疗等生物创新药领域的最新进展。2025JPM大会展示的ADC药物多达数十款，基本为第三代产品，面向肺癌、乳腺癌、肺癌等高发实体瘤，涌现出一大批创新前沿的生物技术公司。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159760":"医疗健康","159992":"创新药","600062":"华润双鹤","600079":"ST人福","600196":"复星医药","600200":"*ST苏吴","600216":"浙江医药","600267":"海正药业","600276":"恒瑞医药","600380":"健康元","600420":"国药现代","600488":"津药药业","600513":"联环药业","600521":"华海药业","600613":"神奇制药","600624":"ST复华","600664":"哈药股份","600774":"汉商集团","601089":"福元医药","603168":"莎普爱思","603207":"小方制药","603229":"奥翔药业","603351":"威尔药业","603367":"辰欣药业","603520":"司太立","603538":"美诺华","603669":"灵康药业","603676":"卫信康","603707":"健友股份","603811":"诚意药业","605116":"奥锐特","605177":"东亚药业","605507":"国邦医药","688117":"圣诺生物","688176":"亚虹医药","688189":"南新制药","688197":"首药控股","688221":"前沿生物","688235":"百济神州","688247":"宣泰医药","688266":"泽璟制药","688302":"海创药业","688321":"微芯生物","688356":"键凯科技","688373":"盟科药业","688428":"诺诚健华","688505":"复旦张江","688506":"百利天恒","688513":"苑东生物","688553":"汇宇制药","688566":"吉贝尔","688578":"艾力斯","688602":"康鹏科技","688658":"悦康药业","688690":"纳微科技","688799":"华纳药厂","BK0183":"MSCI概念","BK0188":"融资融券","BK0012":"证金概念","BK0187":"一线龙头","BK0028":"国家队","BK0175":"白马股","BK0060":"抗癌","BK0196":"行业龙头","BK0239":"医药制造","BK0096":"民营医院"},"translate_title":"Pharmaceutical industry: Looking at the bio-innovative drug pipeline from the JPMorgan Healthcare Conference, focusing on ADCs, bispecific antibodies, cell and gene therapy","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159760":1,"159992":1,"600062":0.9,"600079":0.9,"600196":0.9,"600200":0.9,"600216":0.9,"600267":0.9,"600276":0.9,"600380":0.9,"600420":0.9,"600488":0.9,"600513":0.9,"600521":0.9,"600613":0.9,"600624":0.9,"600664":0.9,"600774":0.9,"601089":0.9,"603168":0.9,"603207":0.9,"603229":0.9,"603351":0.9,"603367":0.9,"603520":0.9,"603538":0.9,"603669":0.9,"603676":0.9,"603707":0.9,"603811":0.9,"605116":0.9,"605177":0.9,"605507":0.9,"688117":0.9,"688176":0.9,"688189":0.9,"688197":0.9,"688221":0.9,"688235":0.9,"688247":0.9,"688266":0.9,"688302":0.9,"688321":0.9,"688356":0.9,"688373":0.9,"688428":0.9,"688505":0.9,"688506":0.9,"688513":0.9,"688553":0.9,"688566":0.9,"688578":0.9,"688602":0.9,"688658":0.9,"688690":0.9,"688799":0.9},"content_text":"2025年第四十三届摩根大通医疗健康年会（JPM大会）盛大召开。国内百济神州、恒瑞医药、信达生物、康方生物等约30家企业参会，分享了多个重磅品种最新成果，中国创新药成为世界舞台上闪耀的新星。我们从本次会议的热点一窥行业创新升级的重点方向，关注抗体偶联药物（Antibody-Drug Conjugate，ADC）、双特异性抗体、细胞与基因治疗等生物创新药领域的最新进展。一、ADC快速发展，第三代技术引领潮头ADC被称为“魔法子弹”，主要是将高特异性的单克隆抗体与具有细胞毒性的小分子药物通过连接子连接起来，利用抗体的靶向性将细胞毒药物精准地递送到靶细胞，从而发挥高效的抗肿瘤作用。2025JPM大会展示的ADC药物多达数十款，基本为第三代产品，面向肺癌、乳腺癌、肺癌等高发实体瘤，涌现出一大批创新前沿的生物技术公司。1.从抗体、连接子、细胞毒（药）物、偶联方式等结构特征来看基本为第三代产品，通过全人源化的单克隆抗体搭载DNA损伤剂（PBD）、拓扑异构酶抑制剂（DXd）等细胞毒性分子，能够实现更强、更好的抗肿瘤活性，具有良好的临床效力。2.开发的适应症逐渐向乳腺癌、卵巢癌、非小细胞肺癌等实体瘤领域过渡，撬动百亿美元规模市场。3.国产ADC进入爆发阶段，科伦博泰、荣昌生物等Biotech活跃度较高。国内拥有较为丰富的ADC在研管线，进入研发后期（包括进入临床Ⅲ期和申请上市阶段）的国产原研产品占全球55%以上。2024年，国产原研（科伦博泰）芦康沙妥珠单抗，授权引进的（华东医药）索米妥昔单抗、（瓴路药业）替朗妥昔等产品上市，我国ADC进入爆发阶段。二、双特异性抗体优势突出，临床潜力加速释放双特异性抗体(双抗)是指一个抗体分子可以与两个不同抗原或同一抗原的两个不同抗原表位相结合，基于桥接激活免疫细胞、协同阻断特定通路等相关原理，相比单抗在增强治疗效果和克服抗药性方面具有更好的表现。本次JPM大会重点展示的双抗品种均表现出较好的临床潜力，上市双抗品种正在积极拓展新适应症或者探索联合治疗改善治疗效果，未上市的品种基本处于临床中后期，预计1-2年内取得关键进展。国内双抗处于领先阶段，2025年有望加速放量。国内目前拥有3款（全球18款）上市双抗和16款进入临床阶段的双抗，适应症主要集中在晚期非小细胞肺癌、宫颈癌等肿瘤领域。已经上市的品种预计迎来规模放量。康方生物的卡度尼利单抗和达沃西单抗通过2024年医保谈判，预计在2025年实现医保结算放量。多个在研品种进入关键节点。如百济神州泽尼达妥单抗申请上市，预计2025年第二季度有往获批上市；康宁杰瑞KN026正在进行三期临床研究，KN026 +白蛋白多西他赛在HER2阳性乳腺癌一线治疗大约在2025年底26年初大概率发布临床成功公告；百利天恒BL-B01D1已被国家药监局纳入突破性治疗品种名单，计划在2025年开启全球注册性临床试验。三、细胞与基因治疗多点开花，CAR-T、核酸药物实现新突破细胞与基因治疗分为细胞治疗与基因治疗，前者是指将是指应用人的自体、同种异体或异种（非人体）的细胞，经体外操作后回输（或植入）人体的治疗方法；后者是指将外源基因（或基因编辑工具）导入靶细胞或组织，替代、补偿、阻断、修正、增加或敲除特定基因以发挥治疗作用。本次JPM大会细胞与基因治疗产品多点开花，围绕嵌合抗原受体T细胞免疫疗法（CAR-T）、核酸药物、基因编辑等前沿领域展出多项重磅品种。CAR-T拓展自身免疫疾病、实体瘤等新适应症，同种异体“现货型”产品逐步攻关中。目前获批的CAR-T产品主要集中在血液瘤领域，且来源为自体T细胞，在攻克实体瘤、实现通用制备等方面存在改善空间。JPM展示的一些临床早期（I期-II期）产品已经有所突破，如allogene公司展示的ALLO-329、ALLO-316两个品种都是经基因技术改造的异体现货CAR-T细胞产品，分别靶向自身免疫疾病和肾细胞癌，前者在临床前试验中表现出较好的细胞毒活性和抗免疫排斥，预计2025年开展临床I期试验；后者有望成为Best-in-Class级别的重磅产品。核酸药物管线丰富，反义核苷酸、基因编辑相关核酸药物（CRISPR-Cas系统）等亮点突出。反义核苷酸药物可以通过碱基互补配对、降解mRNA实现抑制基因表达。2025JPM大会展示的反义核苷酸药物在创新修饰、精准递送等方面呈现出一定的优越性，如IONIS系列药物利用了ligand-Conjugated Antisense（LICA）平台，将反义核苷酸分子与糖/多肽/抗体/Fab片段等偶联，通过ASGR/GLP1R/TFR1等细胞表面受体递送至肝/胰/肌肉等组织和器官。ENTR-601系列利用内体逃逸载体（EEV）平台来解决细胞内递送和内体逃逸问题。基因编辑相关核酸药物技术逐步成熟，CRISPR-Cas系统发挥重要作用。基因编辑是指对生物体遗传物质进行精确和有针对性的修改，目前使用较为广泛的CRISPR-Cas核酸酶具有较好的成药潜力，但同时也存在脱靶效应、递送困难、免疫原性等技术局限，尤其是体内编辑治疗尚未有成熟的产品上市。本次JPM大会intellia公司的2款体内技术产品值得关注，NTLA2002、Nex-z（NTLA-2001）均通过脂质纳米颗粒（LNP）递送CRISPRCas9基因编辑，实现定向敲除基因，在早期临床试验中显示出较好的疗效。风险提示研发及商业化失败、政策落地效果不明显、业绩增长不及预期","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2510827757","isCrawlerRequest":true}